Viewing Study NCT03773302

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:05 AM
Ignite Modification Date: 2026-03-01 @ 9:58 AM
Study NCT ID: NCT03773302
Status: TERMINATED
Last Update Posted: 2024-05-08
First Post: 2018-12-10
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Sponsor: QED Therapeutics, a BridgeBio company
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Cholangiocarcinoma View
None FGFR2 Gene Mutation View
Keywords:

Keywords

Keyword Brief Keyword Text View
None cholangiocarcinoma View
None unresectable cholangiocarcinoma View
None metastatic cholangiocarcinoma View
None fibroblast growth factor receptor inhibitor View
None FGFR2 View
None FGFR2 gene fusions/translocations View
None BGJ398 View